Fresenius Medical Care (NYSE:FMS) Earns Strong-Buy Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research report released on Thursday. The firm issued a strong-buy rating on the stock.

A number of other brokerages have also commented on FMS. Truist Financial boosted their target price on Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Berenberg Bank initiated coverage on Fresenius Medical Care in a report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price objective for the company.

Fresenius Medical Care Trading Down 2.0 %

NYSE:FMS opened at $22.02 on Thursday. The firm has a fifty day simple moving average of $20.97 and a two-hundred day simple moving average of $20.31. Fresenius Medical Care has a 12 month low of $17.93 and a 12 month high of $22.76. The stock has a market capitalization of $12.92 billion, a price-to-earnings ratio of 18.20, a PEG ratio of 1.03 and a beta of 0.91. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42.

Hedge Funds Weigh In On Fresenius Medical Care

Large investors have recently added to or reduced their stakes in the business. Wulff Hansen & CO. lifted its stake in Fresenius Medical Care by 1,809.0% during the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after acquiring an additional 325,439 shares in the last quarter. Moran Wealth Management LLC lifted its position in shares of Fresenius Medical Care by 47.0% during the third quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock valued at $4,971,000 after purchasing an additional 74,621 shares in the last quarter. Quantinno Capital Management LP boosted its holdings in Fresenius Medical Care by 78.9% during the third quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock worth $2,345,000 after purchasing an additional 48,554 shares during the last quarter. Triasima Portfolio Management inc. grew its position in Fresenius Medical Care by 27.4% in the 2nd quarter. Triasima Portfolio Management inc. now owns 85,430 shares of the company’s stock worth $1,631,000 after purchasing an additional 18,360 shares in the last quarter. Finally, Franklin Resources Inc. increased its stake in Fresenius Medical Care by 3.3% in the 3rd quarter. Franklin Resources Inc. now owns 74,640 shares of the company’s stock valued at $1,490,000 after buying an additional 2,386 shares during the last quarter. Institutional investors own 8.25% of the company’s stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.